These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 34899137)

  • 1. Escitalopram-induced epistaxis: A case report.
    AlJhani SA
    J Taibah Univ Med Sci; 2021 Dec; 16(6):938-942. PubMed ID: 34899137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review.
    Edinoff AN; Raveendran K; Colon MA; Thomas BH; Trettin KA; Hunt GW; Kaye AM; Cornett EM; Kaye AD
    Health Psychol Res; 2022; 10(4):39580. PubMed ID: 36425234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feeling blue to seeing red: A case of escitalopram-induced epistaxis.
    Ogundare T; Ologun OA
    Clin Case Rep; 2024 Jul; 12(7):e9128. PubMed ID: 38983874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.
    Hedges DW; Woon FL
    Neuropsychiatr Dis Treat; 2007 Aug; 3(4):455-61. PubMed ID: 19300574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
    Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
    Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anxiety and depression: individual entities or two sides of the same coin?
    Nutt D
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():19-24. PubMed ID: 24930685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.
    Edinoff AN; Akuly HA; Hanna TA; Ochoa CO; Patti SJ; Ghaffar YA; Kaye AD; Viswanath O; Urits I; Boyer AG; Cornett EM; Kaye AM
    Neurol Int; 2021 Aug; 13(3):387-401. PubMed ID: 34449705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for OCD.
    Fineberg NA
    Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
    Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
    Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram: a second-generation SSRI.
    Owens MJ; Rosenbaum JF
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):34-9. PubMed ID: 15131491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Practice Guideline: Nosebleed (Epistaxis).
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1_suppl):S1-S38. PubMed ID: 31910111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary.
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1):8-25. PubMed ID: 31910122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ecchymosis associated with the use of fluoxetine: case report].
    Mirsal H; Kalyoncu A; Pektaş O
    Turk Psikiyatri Derg; 2002; 13(4):320-4. PubMed ID: 12794649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.
    Kirino E
    Patient Prefer Adherence; 2012; 6():853-61. PubMed ID: 23271894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine: an update of its use in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabbit Syndrome Likely Induced by Escitalopram: A Case Report.
    Nimber JS; Aggarwal A
    J Pharm Technol; 2014 Oct; 30(5):179-181. PubMed ID: 34860880
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of serotonin and noradrenaline in anxiety.
    Blier P; El Mansari M
    Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():16-23. PubMed ID: 24926868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C; Svestka J
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.